Detalhe da pesquisa
1.
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
BMC Cancer
; 24(1): 446, 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600471
2.
Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study.
Cancers (Basel)
; 13(7)2021 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33916610
3.
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
Clin Cancer Res
; 24(10): 2276-2284, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29506988
4.
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.
Mol Cancer Ther
; 16(9): 1999-2007, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28626084
5.
Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.
Oncol Lett
; 12(1): 727-730, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27347207
6.
The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Cancer Treat Rev
; 36 Suppl 1: S1-10, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20189053
7.
Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Breast Cancer
; 17(3): 205-11, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19551465